Tags

Type your tag names separated by a space and hit enter

Treatment of Parkinson's disease.
Curr Opin Neurol Neurosurg. 1993 Jun; 6(3):339-43.CO

Abstract

The treatment of Parkinson's disease is reviewed. The rationale for using selegiline (deprenyl) as the first treatment in recently diagnosed patients is presented. Selegiline delays the need for levodopa; however, it is unclear whether this results from a symptomatic or a neuroprotective effect of selegiline. Levodopa combined with a decarboxylase inhibitor is the principal treatment for patients with moderate or marked symptoms. There is little evidence that levodopa has a deleterious effect on the court of Parkinson's disease. The relationship of levodopa to dyskinesias and response fluctuations is discussed. Pharmacokinetic and pharmacodynamic studies suggest that continuous dopaminergic stimulation may be superior to intermittent pulse therapy. The best approximation to continuous stimulation is the use of long-acting levodopa-carbidopa preparations supplemented by dopamine agonists.

Authors+Show Affiliations

Barrow Neurological Institute, St. Joseph's Medical Center, Phoenix, Arizona.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8507903

Citation

Lieberman, A. "Treatment of Parkinson's Disease." Current Opinion in Neurology and Neurosurgery, vol. 6, no. 3, 1993, pp. 339-43.
Lieberman A. Treatment of Parkinson's disease. Curr Opin Neurol Neurosurg. 1993;6(3):339-43.
Lieberman, A. (1993). Treatment of Parkinson's disease. Current Opinion in Neurology and Neurosurgery, 6(3), 339-43.
Lieberman A. Treatment of Parkinson's Disease. Curr Opin Neurol Neurosurg. 1993;6(3):339-43. PubMed PMID: 8507903.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of Parkinson's disease. A1 - Lieberman,A, PY - 1993/6/1/pubmed PY - 1993/6/1/medline PY - 1993/6/1/entrez SP - 339 EP - 43 JF - Current opinion in neurology and neurosurgery JO - Curr Opin Neurol Neurosurg VL - 6 IS - 3 N2 - The treatment of Parkinson's disease is reviewed. The rationale for using selegiline (deprenyl) as the first treatment in recently diagnosed patients is presented. Selegiline delays the need for levodopa; however, it is unclear whether this results from a symptomatic or a neuroprotective effect of selegiline. Levodopa combined with a decarboxylase inhibitor is the principal treatment for patients with moderate or marked symptoms. There is little evidence that levodopa has a deleterious effect on the court of Parkinson's disease. The relationship of levodopa to dyskinesias and response fluctuations is discussed. Pharmacokinetic and pharmacodynamic studies suggest that continuous dopaminergic stimulation may be superior to intermittent pulse therapy. The best approximation to continuous stimulation is the use of long-acting levodopa-carbidopa preparations supplemented by dopamine agonists. SN - 0951-7383 UR - https://www.unboundmedicine.com/medline/citation/8507903/Treatment_of_Parkinson's_disease_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=8507903.ui DB - PRIME DP - Unbound Medicine ER -